Loading…
Maker of diagnostic imaging agents (radiopharmaceuticals) used in cardiac, oncology and other nuclear-medicine imaging procedures.
Maker of diagnostic imaging agents (radiopharmaceuticals) used in cardiac, oncology and other nuclear-medicine imaging procedures.
Sells imaging agents by the dose to hospitals and imaging centres, mostly through radiopharmacy networks that make and deliver them within hours because the isotopes decay quickly. Pylarify, used in prostate-cancer scans, is the main growth line, and Definity, an ultrasound contrast agent, the longer-standing one. Reimbursement terms matter.
Moat: narrow (regulatory licence, IP / patents, distribution). FDA-approved radiopharmaceutical products with specialized short-shelf-life manufacturing/distribution create barriers to entry.
Headquarters: Bedford, Massachusetts, USA · Founded: 1956 · Employees: 1,193
Size Lantheus (LNTH) is a United States Health Care company (Medical Specialties) with a market value of $6.57B, the 992nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $100.61 on 6 Nov 2026.
Performance Over six months the shares gained 8.1%, against +27.7% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 2.4% over the last twelve months (peer median +6.3%); the operating margin is 19.4% (peer median 13.9%).
Valuation It trades at 17.5× forward earnings against a peer median of 21.0× (6th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -36 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 11.5 points above its cost of capital (6.3% WACC).
Credit Lantheus has 1 bond outstanding ($575M).
Short interest Short interest is 5.6% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.56B | $1.54B | $1.53B | $1.30B | $935M |
| Revenue growth | — | +1% | +18% | +39% | — |
| Gross profit | $936M | $942M | $988M | $848M | $582M |
| EBITDA | $391M | $382M | $510M | $553M | $119M |
| Net income | $275M | $234M | $312M | $327M | $28.1M |
| Free cash flow | $388M | $354M | $491M | $259M | $263M |
| Capital expenditure | $25.0M | $41.5M | $79.6M | $46.6M | $18.3M |
| Total debt | $625M | $623M | $621M | $619M | $586M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Lantheus LNTH | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% |
| GE HealthCare GEHC | $37.2B | +30% | +7% | 14% | 15.4× | 4.3% |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 18.4× | 1.7% |
| Telix Pharmaceuticals TLX.AX | $3.22B | -6% | +27% | -1% | 36.8× | n/a |
| Siemens Healthineers SHL.DE | $55.9B | +31% | -1% | 15% | 18.9× | 9.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LNTH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.5% | +9.4% | 5th lowest of 21 |
| 6-month return | +8.1% | +27.7% | 3rd lowest of 21 |
| Distance from 52-week high | -10.1% | -9.3% | 10th lowest of 21 |
| Revenue growth (TTM) | +2.4% | +6.3% | 9th lowest of 21 |
| Operating margin | 19.4% | 13.9% | 8th highest of 21 |
| Forward P/E | 17.5× | 21.0× | 6th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -0.5% | 11.2% | least demanding of 19 |
| Growth delivered (Del g) | +35.3% | +9.4% | 2nd highest of 19 |
| Hurdle (Req g minus delivered) | -35.9 pp | +1.2 pp | least demanding of 19 |
| ROIC minus cost of capital | +11.5 pp | +2.8 pp | 4th highest of 21 |
| EV / EBITDA | 16.9× | 13.1× | 7th most expensive of 18 |
| Net debt / EBITDA | 0.1× | 0.9× | 7th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lantheus LNTH | United States | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% | +35.3% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% | +4.6% |
| Teleflex TFX | United States | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% | -4.7% |
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% | +12.6% |
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% | +18.8% |
| Cochlear COH.AX | Australia | $7.05B | +55% | -1% | 13% | 29.4× | 24.1% | +9.3% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% | +15.7% |
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 37% | 38.5× | 8.7% | +40.1% |
| Getinge GETI-B.ST | Sweden | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% | +3.2% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% | +6.3% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 13% | 19.9× | 11.5% | +8.2% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | 14% | 25.5× | n/a | n/a |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% | +7.3% |
| Globus Medical GMED | United States | $9.54B | -9% | +20% | 22% | 14.1× | 5.5% | +30.1% |
Lantheus has 1 bond outstanding with $575M face value.